{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
chlorphenesin carbamate
to a specific field?
Status:
Investigational
Source:
NCT00915356: Phase 2 Interventional Completed Atrial Fibrillation
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
AZD1305, an antiarrhythmic agent, blocks the hERG potassium channel, the L-type calcium, and the Sodium channel protein Nav1.5. AZD1305 participated in clinical trials for the management of atrial fibrillation and Left ventricular dysfunction. The benefit-risk profile was judged as unfavorable and the AZD1305 development programme was discontinued.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mitsubishi Tanabe Pharma was developing Sofigatran, a thrombin inhibitor, for the treatment of deep vein thrombosis. Sofigatran, is a direct oral thrombin inhibitor with a competitive binding mechanism. It has been assessed in a phase II trial for the treatment of deep vein thrombosis The compound was in phase II clinical trial for the treatment of DVT. Results of this trial have not been published and the clinical development of sofigatran has been discontinued by Mitsubishi Tanabe Pharma in 2007.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Uredepa, a thiotepa derivative, is a antineoplastic, alkylating agent. It has also been used experimentally as an insect chemosterilant.
Status:
Investigational
Source:
NCT01308164: Not Applicable Interventional Completed Type 1 Diabetes
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (RACEMIC)
Pamatolol is a beta-Adrenergic receptor antagonist was studied as an Antiarrhythmic agent. The phase I clinical trial has shown that the drug was relatively cardioselective in man. Information about the further development of this drug is not available.
Class (Stereo):
CHEMICAL (ABSOLUTE)
LASINAVIR, a hydroxyethylene derivative, is highly specific human immunodeficiency virus (HIV) protease inhibitor with an IC50 of 1 nM. Its clinical development was discontinued.
Status:
Investigational
Source:
USAN:CEFUROXIME PIVOXETIL [USAN]
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Cefuroxime Pivoxetil is an ester prodrug of cefuroxime, a semisynthetic, broad-spectrum, beta-lactamase-resistant, second-generation cephalosporin with antibacterial activity. Cefuroxime binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.
Class (Stereo):
CHEMICAL (UNKNOWN)
Cicarperone is decahydroquinoline derivative with local anesthetic action. In ex vivo models Cicarperone protected anesthetized guinea-pigs against ouabain-induced ventricular fibrillation and increased the lethal dose of ouabain. Unlike most drugs with local anesthetic properties, Cicarperone did not depress contractions in isolated atria but increased them. Cicarperone reduces the spontaneous frequency, maximum follow frequency and conduction velocity of rabbit isolated atria. Cicarperone had no blocking action on the chronotropic or positive inotropic actions of isoprenaline on isolated atrial muscle. In vivo evaluation of Cicarperone in anesthetized dogs shows that Cicarperone caused small dose-related bradycardia and a large dose-related decrease in peripheral vascular resistance. Ciclactate has never been marketed in the US and EU.
Status:
Investigational
Source:
NCT00088504: Phase 2 Interventional Completed Hepatitis C
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Merimepodib has immunosuppressive activity. It targets hepatitis C indirectly through the inhibition of inositol monophosphate dehydrogenase, which exerts an acute antiproliferative effect on lymphocyte proliferation due to their almost exclusive dependence on the de novo pathway for synthesis of guanosine. Phase II clinical trial study of merimepodib for the treatment of HCV infection and psoriasis were completed. The poor pharmacokinetic-pharmacodynamic results have resulted in discontinuation of clinical trials.
Status:
Investigational
Source:
NCT00803556: Phase 1 Interventional Completed Solid Tumor
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Alvespimycin (17-desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin) (17-DMAG; NSC 707545) is an inhibitor of the molecular chaperone heat shock protein HSP90. Alvespimycin is a derivative of antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction. Alvespimycin was studied in clinical trials for the treatment of solid tumors and hematologic malignancies however its development was discontinued.
